XTL Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2024: 9.03%

XTL Biopharmaceuticals Ltd (H2K2) has an Asset Resilience Ratio of 9.03% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XTL Biopharmaceuticals Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€772.00K

≈ $902.55K USD Cash + Short-term Investments

Total Assets

€8.55 Million

≈ $10.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how XTL Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see H2K2 total assets.

Liquid Assets Composition Over Time

This chart breaks down XTL Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore H2K2 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€772.00K	9.03%
Total Liquid Assets	€772.00K	9.03%

Asset Resilience Insights

Limited Liquidity: XTL Biopharmaceuticals Ltd maintains only 9.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

XTL Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare XTL Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for XTL Biopharmaceuticals Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.03%	€772.00K ≈ $902.55K	€8.55 Million ≈ $10.00 Million	-15.91pp
2023-12-31	24.94%	€605.00K ≈ $707.31K	€2.43 Million ≈ $2.84 Million	-13.93pp
2022-12-31	38.87%	€1.63 Million ≈ $1.90 Million	€4.19 Million ≈ $4.89 Million	-8.85pp
2021-12-31	47.72%	€3.16 Million ≈ $3.69 Million	€6.62 Million ≈ $7.74 Million	+10.64pp
2020-12-31	37.08%	€2.41 Million ≈ $2.82 Million	€6.50 Million ≈ $7.60 Million	+5.56pp
2019-12-31	31.52%	€2.27 Million ≈ $2.66 Million	€7.21 Million ≈ $8.43 Million	-25.24pp
2018-12-31	56.76%	€4.87 Million ≈ $5.69 Million	€8.57 Million ≈ $10.03 Million	+14.17pp
2017-12-31	42.59%	€2.81 Million ≈ $3.28 Million	€6.59 Million ≈ $7.70 Million	+28.87pp
2016-12-31	13.72%	€414.00K ≈ $484.01K	€3.02 Million ≈ $3.53 Million	--

pp = percentage points

About XTL Biopharmaceuticals Ltd

F:H2K2 Germany Biotechnology

Market Cap

$6.31 Million

€5.39 Million EUR

Market Cap Rank

#30586 Global

#2673 in Germany

Share Price

€2.28

Change (1 day)

+23.24%

52-Week Range

€0.45 - €2.80

All Time High

€8.26